{
    "ticker": "JANX",
    "name": "Janux Therapeutics, Inc.",
    "description": "Janux Therapeutics, Inc. is an innovative biotechnology company focused on developing next-generation immunotherapies for cancer treatment. Founded in 2017 and headquartered in La Jolla, California, Janux is dedicated to harnessing the power of the immune system to fight cancer more effectively and with fewer side effects than traditional therapies. The company specializes in its proprietary T-cell engager platform, which is designed to create highly targeted therapies that can activate the immune system specifically against tumor cells. Janux's lead product candidates aim to address various cancer types, including solid tumors, and the company is committed to advancing its pipeline through rigorous clinical trials. With a strong emphasis on research and development, Janux collaborates with academic institutions and industry partners to enhance its therapeutic offerings and improve patient outcomes. The company's mission is to transform the cancer treatment landscape, providing hope to patients and their families through innovative solutions that leverage the body's natural defenses.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "La Jolla, California, USA",
    "founded": "2017",
    "website": "https://www.januxtherapeutics.com",
    "ceo": "David J. Dimmock",
    "social_media": {
        "twitter": "https://twitter.com/JanuxTherapeutics",
        "linkedin": "https://www.linkedin.com/company/janux-therapeutics/"
    },
    "investor_relations": "https://ir.januxtherapeutics.com",
    "key_executives": [
        {
            "name": "David J. Dimmock",
            "position": "CEO"
        },
        {
            "name": "Kurt K. Kohn",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapies",
            "products": [
                "JANX-001",
                "JANX-002"
            ]
        }
    ],
    "seo": {
        "meta_title": "Janux Therapeutics, Inc. | Next-Generation Cancer Immunotherapies",
        "meta_description": "Explore Janux Therapeutics, Inc., a biotech company dedicated to developing innovative immunotherapies for cancer treatment. Learn about our mission and product pipeline.",
        "keywords": [
            "Janux Therapeutics",
            "Biotechnology",
            "Cancer Immunotherapy",
            "T-cell Engagers",
            "Immunotherapy",
            "Cancer Treatment"
        ]
    },
    "faq": [
        {
            "question": "What is Janux Therapeutics focused on?",
            "answer": "Janux Therapeutics is focused on developing next-generation immunotherapies for cancer treatment."
        },
        {
            "question": "Who is the CEO of Janux Therapeutics?",
            "answer": "David J. Dimmock is the CEO of Janux Therapeutics, Inc."
        },
        {
            "question": "Where is Janux Therapeutics headquartered?",
            "answer": "Janux Therapeutics is headquartered in La Jolla, California, USA."
        },
        {
            "question": "What are Janux's main products?",
            "answer": "Janux's main products include JANX-001 and JANX-002, which are immunotherapies targeting cancer."
        },
        {
            "question": "When was Janux Therapeutics founded?",
            "answer": "Janux Therapeutics was founded in 2017."
        }
    ],
    "competitors": [
        "BMY",
        "AMGN",
        "REGN",
        "EXEL"
    ],
    "related_stocks": [
        "MRNA",
        "NVAX",
        "PFE",
        "GILD"
    ]
}